Archive


Category: Angelini Pharma

  • Drug-resistant epilepsy drug Ontozry backed by NICE

    NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant […]

  • Angelini and Arvelle create neurology player with $960m merger

    There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. Angelini is an international pharma company that is part of the privately-owned Italian Angelini Group, while Arvelle is focused on […]